00000nam 2200000zi 4500 9.945863 CaOODSP 20250313081456 m o d f cr mn||||||||| 241204e202502##onca obs f000 0 eng d 9780660747705 CaOODSP eng rda CaOODSP n-cn--- y1y2 H82-55/2025E-PDF Private drug plans in Canada : expenditure report, 2018-2023. Ottawa, ON : Patented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, February 2025. ©2025 1 online resource (vi pages, 1 unnumbered page, 41 pages) : colour illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Issued also in French under title: Régimes privés d'assurance-médicaments au Canada : rapport sur les dépenses, 2018-2023. On cover: NPDUIS, National Prescription Drug Utilization Information System. Includes bibliographical references. "This report provides a comprehensive analysis of trends in prescription drug expenditures from the perspective of Canadian private drug plans. From 2018 to 2023, private pay-direct drug plans experienced a compound annual growth rate of 7.1%, with a significant 12.9% increase in 2023. This growth in 2023 was uneven across its two main components: drug costs (which saw an increase of 14.1%) and dispensing costs (which saw an increase of 4.5%). Over past years, rising expenditures in private plans were consistently driven primarily by significant increases in the use of newer and higher-cost drugs. A comparative analysis with Canadian public drug plans is also included in the report. …"--Executive summary, page iv. Pharmaceutical services insurance Canada Costs Statistics. Prescription pricing Canada Statistics. Statistics lcgft Canada. Patented Medicine Prices Review Board, issuing body. Régimes privés d'assurance-médicaments au Canada : (CaOODSP)9.945864 PDF 988 KB https://publications.gc.ca/collections/collection_2025/cepmb-pmprb/H82-55-2025-eng.pdf HTML N/A https://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/private-drug-plans-2018-2023.html